Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Budesonide suspension for inhalation (Pulmicort Respules)

Treatment of bronchial asthma. It can replace or reduce oral steroid therapy. It is recommended to use inhaled budesonide suspension when other methods of steroid treatment are not suitable. More role
App download minus 10 yuan
Common name:
budesonide suspension for inhalation
Product No.:
B14200071587
Approval No.:
H20140475 (inquired by the State Drug Administration)
Jianke price:
¥99.00
Product specification:
2ml: 1mg * 30 pieces 2ml: 0.5mg * 30 pieces 1mg: 2ml * 5 pieces
Manufacturer:
AstraZeneca Pty Ltd
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Budesonide suspension for inhalation (Pulmicort Respules)
Main raw materials Budesonide.
Main role Treatment of bronchial asthma. It can replace or reduce oral steroid therapy. It is recommended to use inhaled budesonide suspension when other methods of steroid treatment are not suitable.
Product specification 1mg: 2ml * 5 pieces
Usage and dosage See "Introduction to use" for details budesonide suspension for inhalation If asthma worsens, the daily number and / or total amount of budesonide need to be increased. Budesonide suspension for inhalation should be administered through a suitable atomizer. According to different atomizers, the actual inhalation dose of the patient is 40 ~ 60% of the marked amount. Atomization time and output dose depend on flow rate, atomizer volume and liquid drug capacity. For most atomizers, the appropriate solution capacity is 2 ~ 4 ml. Inhalation Budesonide Suspension may cause some deposition during storage. If a completely stable suspension cannot be formed after oscillation, it shall be discarded. Initial dose, severe asthma or reduced oral glucocorticoid dose Adults: 1 ~ 2mg once, twice a day. Children: 0.5 ~ 1mg once, twice a day. Maintenance dose The maintenance dose should be individualized and should be the lowest dose to keep the patient asymptomatic. Recommended dose: Adults: 0.5 ~ 1mg once, twice a day. Children: 0.25 ~ 0.5mg once, twice a day. See the inner packaging instructions for details.
manufacturing enterprise AstraZeneca Pty Ltd
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Budesonide suspension for inhalation (Pulmicort Respules)

[common name] budesonide suspension for inhalation

[specification and model] 1mg: 2ml * 5 pieces

[manufacturer] AstraZeneca Pty Ltd

[drug type] Western medicine

[approval No.] H20140475

[validity period] 24 months

[functional indications] Treatment of bronchial asthma. It can replace or reduce oral steroid therapy. It is recommended to use inhaled budesonide suspension when other methods of steroid treatment are not suitable.

[usage and dosage] See "Introduction to use" for details budesonide suspension for inhalation If asthma worsens, the daily number and / or total amount of budesonide need to be increased. Budesonide suspension for inhalation should be administered through a suitable atomizer. According to different atomizers, the actual inhalation dose of the patient is 40 ~ 60% of the marked amount. Atomization time and output dose depend on flow rate, atomizer volume and liquid drug capacity. For most atomizers, the appropriate solution capacity is 2 ~ 4 ml. Inhalation Budesonide Suspension may cause some deposition during storage. If a completely stable suspension cannot be formed after oscillation, it shall be discarded. Initial dose, severe asthma or reduced oral glucocorticoid dose Adults: 1 ~ 2mg once, twice a day. Children: 0.5 ~ 1mg once, twice a day. Maintenance dose The maintenance dose should be individualized and should be the lowest dose to keep the patient asymptomatic. Recommended dose: Adults: 0.5 ~ 1mg once, twice a day. Children: 0.25 ~ 0.5mg once, twice a day. See the inner packaging instructions for details.

[adverse reactions] The incidence ranged from 1% to ≤ 3% (by body system) The following information includes all adverse events with an incidence of 1 to ≤ 3%. Regardless of the correlation with drug treatment, at least one adverse event in the inhaled budesonide suspension group exceeded that in the placebo group. Systemic reactions: allergic reaction, chest pain, fatigue, flu like symptoms Respiratory system: Wheezing Damage of defense mechanism: herpes simplex, external ear infection, infection Central and peripheral nervous system: dysphonia, hyperkinesia Skin and skin appendages: eczema, purulent herpes, pruritus Hearing and vestibule: earache Vision: eye infection Psychiatry: anorexia, emotional instability Musculoskeletal system: fracture, myalgia Application site: contact dermatitis Platelets, bleeding and coagulation: purpura Leukocytes and resistance: cervical lymphadenopathy In three open studies, 447 asthmatic children who received inhaled budesonide suspension (average total daily dose 0.5-1 mg) and 223 asthmatic children who received traditional treatment had a similar incidence of adverse events after one-year follow-up. In the published literature, the results of long-term open clinical trials, or the post marketing reports of all inhaled budesonide preparations in the world, the occasional adverse events (< 1%) include: rapid or delayed allergic reactions, including rash, contact dermatitis, urticaria, angioedema and bronchospasm; Symptoms of adrenocortical hypofunction and adrenal hyperfunction; Glaucoma and cataract; Psychiatric symptoms, including depression, aggressive reaction, irritability, anxiety and psychosis; And bone diseases, including avascular necrosis of the femoral head and osteoporosis. Budesonide was well tolerated. Most adverse reactions were mild and localized. The systemic effects and oropharyngeal complications caused by budesonide are dose-related. See the inner packaging instructions for details.

[precautions] General matters 1. Athletes should use it with caution. 2. During steroid withdrawal, some patients may have symptoms related to oral steroid withdrawal, such as joint and / or muscle pain, burnout and depression, even if their respiratory function can be maintained or even improved. 3. Because budesonide can enter the circulatory system, especially at higher doses, it may have systemic activity. Therefore, HPA inhibition may occur when taking budesonide suspension for inhalation exceeding the recommended dose (see [usage and dosage]) or when it is not titrated to the lowest effective dose during treatment. Because individuals have different sensitivities to the effects of cortisol production, physicians should consider this information when prescribing budesonide suspension. 4. Due to the possibility of systemic absorption of inhaled steroids, any systemic steroid effects in patients treated with inhaled budesonide suspension should be observed. Patients with postoperative or adrenal insufficiency need close observation. 5. During treatment, a few patients may have some effects of systemic steroid treatment, such as adrenal hyperfunction, decreased bone mineral density, and adrenal suppression, especially when treated with higher doses. If such changes occur, the use of inhaled budesonide suspension should be gradually reduced. This withdrawal scheme is in line with the recognized asthma symptom management procedure and the reduction strategy of systemic steroids. 6. The potential impact of continuous treatment with inhaled budesonide suspension on the growth rate of children needs to be weighed in combination with the clinical benefits and risks of alternative treatment options. In order to minimize the systemic effects of inhaled steroids including Pulmicort Respules, each patient receiving treatment should be titrated to his / her lowest effective dose (see [precautions] and [medication for children]). 7. Although in the clinical study, the patient has been treated with budesonide suspension for up to 1 year, the local and systemic effects of long-term use in human body are not completely clear. In particular, the effects of long-term use on the development or immunity of oral cavity, pharynx, trachea and lung are not clear. 8. In the clinical study, some patients had local Candida albicans infection in the mouth and pharynx. The incidence of inhaled budesonide suspension treatment group was similar to that of placebo control group. In the event of such an infection, appropriate antifungal treatment and / or discontinuation of treatment with inhaled budesonide suspension may be required. 9. Patients with active or inactive tuberculosis infection in respiratory tract, untreated systemic fungal, bacterial, viral or parasitic infection, or ocular herpes simplex should be cautious. 10. After inhaled steroid treatment, there are few cases of glaucoma, elevated intraocular pressure and cataract. 11. Patients who switch from systemic steroid therapy to inhaled steroid therapy need special care, because there have been deaths caused by adrenocortical insufficiency during or after the conversion from systemic steroid therapy to systemic inhaled steroid therapy. The recovery of HPA axis function usually takes several months after systemic steroid withdrawal. Patients treated with prednisone (or equivalent oral steroids) of 20 mg or more on the previous day were the most affected, especially when the systemic steroids were completely withdrawn. 12. During the inhibition of HPA axis, patients may have symptoms or signs of adrenocortical insufficiency when they encounter trauma, surgery, infection (especially gastroenteritis) or other conditions related to severe electrolyte loss. Although inhaled budesonide suspension can control asthma symptoms under the above conditions, it can not provide normal physiological amount of steroids and mineralocorticoid activity in response to emergencies at the clinically recommended dose. Patients need additional oral steroids during stress response or severe asthma attack. These patients are advised to take warning cards with them. 13. Patients who change from oral steroids to inhaled budesonide suspension should be withdrawn slowly. During withdrawal, the patient's pulmonary function (FEV1 or AMPEF) should be closely observed, β- Agonist use and asthma symptoms. In addition, symptoms associated with adrenocortical insufficiency, such as fatigue, burnout, weakness, nausea and vomiting, and hypotension, need to be observed. 14. Patients who have previously received systemic treatment with high-dose steroids may have early allergic symptoms or other immune system diseases, such as rhinitis, conjunctivitis, eosinophilia, eczema and arthritis. 15. Patients using immunosuppressive drugs are more likely to develop infection than healthy individuals. For example, for sensitive patients using immunosuppressive steroids, the pathogenesis of chickenpox or measles is more serious and even fatal. Children or adults who have not suffered from these diseases or have not been immunized should avoid such infections. How the dose, route and duration of steroid therapy affect the risk of infection is unclear. The impact of underlying disease and / or previous steroid treatment on the patient's risk of infection is also unclear. 16. There was no study of patients with chickenpox and measles infection receiving inhaled steroids. In a clinical study, the immune response of asthmatic children aged 12 months to 8 years after inhalation of budesonide mixture was investigated (see the section on "medication for children"). 17. If patients receiving immunosuppressive dose steroids are exposed to the source of varicella virus infection, they may need to be treated with varicella zoster immunoglobulin (VZIG) or mixed intravenous immunoglobulin (IVIG). If the patient is exposed to the source of measles virus infection, mixed intramuscular immunoglobulin (Ig) may be required for preventive treatment. (refer to their drug instructions for a detailed description of the prescription information of VZIG and Ig). 18. Budesonide is not a bronchodilator, so it should not be used to quickly relieve acute bronchospasm or other acute attacks of asthma. 19. When used together with other inhaled asthma drugs, bronchospasm may occur after taking the medicine, accompanied by the immediate aggravation of wheezing. If acute bronchospasm occurs after inhalation of budesonide suspension, it must be treated immediately with a quick acting inhaled bronchodilator, discontinue inhalation of budesonide suspension, and take other alternative treatments. 20. During the treatment of inhaled budesonide suspension, if asthma does not respond to the usual amount of bronchodilator, contact the doctor immediately. Please read the instructions carefully and follow the doctor's advice.

[taboo] Allergic to budesonide or any other ingredients.

[listing Permit Holder] AstraZenecaPtyLtd

[packaging unit] bag

[main ingredients] Budesonide.

[character] This product is a fine particle suspension. After standing, there is fine particle precipitation. After shaking, it becomes a white or quasi white suspension.

[applicable population] unlimited

[medication for pregnant and lactating women] Medication for pregnant women Teratogenic effect: FDA classified it as pregnancy safety grade B - budesonide has teratogenicity and embryotoxicity to rabbits and rats like other corticosteroids. In one study, rabbits received 25 UG / kg (calculated based on UG / M [sup] 2 [/ sup], which is lower than the maximum recommended daily inhalation dose for adults), and rats received 500 UG / kg (calculated based on UG / M [sup] 2 [/ sup], which is about 4 times the maximum recommended daily inhalation dose for adults), resulting in fetal loss and infant weight loss. In another study on rats, no teratogenic effect and embryotoxicity were observed after inhalation administration at a dose of 250ug / KQ (about twice the maximum recommended daily inhalation dose for adults based on UG / M [sup] 2 [/ sup]). Medication for lactating women Like other steroids, budesonide can be secreted into human milk. The relevant data of budesonide dry powder inhaler show that the total daily oral intake of budesonide by infants through milk is about 0.3% - 1% of that of mothers. There is no study on lactating women using inhaled budesonide suspension; However, it can be expected that infants will also receive a certain percentage of budesonide from the mother by sucking milk. Therefore, lactating women can only be treated with inhaled budesonide suspension when clinical treatment is needed. Doctors need to weigh the benefits of breastfeeding for mothers and infants against the potential risks of infant exposure to trace amounts of budesonide. See the inner packaging instructions for details.

[medication for children] See [usage and dosage]. See the inner packaging instructions for details.

[medication for elderly patients] Same as adult [usage and dosage] In three clinical trials of inhaled budesonide suspension in adult patients, 65 (30%) of all 215 patients were over 65 years old and 22 (10%) were over 75 years old. There was no difference in safety indicators between these patients and younger patients. Other clinical reports or medical observations did not find differences between elderly patients and younger patients.

[storage] Sealed and protected from light.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Budesonide suspension for inhalation (Pulmicort Respules)

    ¥99.00

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!